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Venu Menon, MD,{ E. Murat Tuzcu, MD,{ David Wood, MD,* Lars G. Svensson, MD, PHD,{ Martin B. Leon, MDyABSTRACTOBJECTIVES The purpose of this study was to determine the safety and effectiveness of the SAPIEN XT versus SAPIEN
systems (Edwards Lifesciences, Irvine, California) in patients with symptomatic, severe aortic stenosis (AS) who were not
candidates for surgery.
BACKGROUND Transcatheter aortic valve replacement (TAVR) has become the standard of care for inoperable patients
with severe, symptomatic AS. In the PARTNER (Placement of Aortic Transcatheter Valves) IB trial, a reduction in all-cause
mortality was observed in patients undergoing TAVR with the balloon-expandable SAPIEN transcatheter heart valve
compared with standard therapy, but the SAPIEN valve was associated with adverse periprocedural complications,
including vascular complications, major bleeding, and paravalvular regurgitation. The newer, low-proﬁle SAPIEN XT
system was developed to reduce these adverse events.
METHODS A total of 560 patients were enrolled at 28 sites in the United States from April 2011 to February 2012.
Patients were randomized to receive the SAPIEN or SAPIEN XT systems. The primary endpoint was a nonhierarchical
composite of all-cause mortality, major stroke, and rehospitalization at 1 year in the intention-to-treat population,
assessed by noninferiority testing. Pre-speciﬁed secondary endpoints included cardiovascular death, New York Heart
Association functional class, myocardial infarction, stroke, acute kidney injury, vascular complications, bleeding, 6-min
walk distance, and valve performance (by echocardiography).
RESULTS Both overall and major vascular complications were higher at 30 days in patients undergoing TAVR with
SAPIEN compared with SAPIEN XT (overall: 22.1% vs. 15.5%; p ¼ 0.04; major: 15.2% vs. 9.5%; p ¼ 0.04). Bleeding
requiring blood transfusions was also more frequent with SAPIEN compared with SAPIEN XT (10.6% vs. 5.3%; p ¼ 0.02).
At 1-year follow-up, the nonhierarchical composite of all-cause mortality, major stroke, or rehospitalization was similar
(37.7% SAPIEN vs. 37.2% SAPIEN XT; noninferiority p value <0.002); no differences in the other major pre-speciﬁed
endpoints were found.
CONCLUSIONS In inoperable patients with severe, symptomatic AS, the lower-proﬁle SAPIEN XT is noninferior to
SAPIEN with fewer vascular complications and a lesser need for blood transfusion. (The PARTNER II Trial: Placement of
AoRTic TraNscathetER Valves; NCT01314313) (J Am Coll Cardiol Intv 2015;8:1797–806) © 2015 by the American College
of Cardiology Foundation.
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1798T ranscatheter aortic valve replace-ment (TAVR) has become the stan-dard of care for patients with
severe, symptomatic aortic stenosis (AS)
who are at prohibitive surgical risk or who
possess unfavorable anatomic features for
surgical aortic valve replacement. In the
PARTNER (Placement of Aortic Transcatheter
Valves) IB trial, a reduction in all-cause mor-
tality was observed over 5 years in patients
deemed unsuitable for surgical aortic valve
replacement undergoing TAVR with theballoon-expandable SAPIEN transcatheter heart valve
(Edwards Lifesciences, Irvine, California) compared
with standard therapy (1–4). These ﬁndings, as well
as those from subsequent trials and large interna-
tional registries (5–10), have led to a Class I indication
for TAVR in the treatment of symptomatic patients
with inoperable, severe AS in all major valve guide-
lines (11,12).SEE PAGE 1807Yet despite the safety and efﬁcacy of the SAPIEN
valve, TAVR procedures were still associated
with high rates of adverse periprocedural complica-
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tion, balloon-expandable SAPIEN XT valve and its
lower-proﬁle delivery system were designed to
reduce many of these adverse events. However,
whether these design changes result in improved
outcomes with TAVR remains unknown. We therefore
performed a randomized evaluation of the SAPIEN XT
compared with the SAPIEN valve as part of the
PARTNER IIB study to assess the newer, low-proﬁle
device in inoperable patients with severe AS.
METHODS
PATIENT SELECTION. Patients with severe AS and
New York Heart Association (NYHA) functional class
$II were enrolled into the PARTNER II trial. Severe
AS was deﬁned as an aortic valve area #0.8 cm2, a
mean aortic valve gradient $40 mm Hg, a peak aortic
jet velocity $4.0 m/s, or an indexed aortic valve
effective oriﬁce area <0.5 cm2/m2.
The PARTNER II study consisted of 2 parallel,
independently powered, randomized controlled
multicenter trials (cohorts A and B) and 6 nested reg-
istries (NR1 to NR6). Cohort A consisted of operable
patients who were considered moderate- or high-
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1799of Thoracic Surgeons (STS) risk score $4%. These
patients were randomized to TAVR with SAPIEN XT or
surgical aortic valve replacement. Cohort B consisted
of inoperable patients who had coexisting conditions
that would be associated with a predicted probability
of $50% of either death or serious irreversible mor-
bidity at 30 days after treatment. These patients were
randomized to transfemoral TAVR with either SAPIEN
or SAPIEN XT. Inoperable patients were enrolled in the
nested registries if they lacked appropriate trans-
femoral access and required transapical or transaortic
TAVR (NR1 and NR4, respectively), possessed small
femoral vessel diameters of 6 to 7 mm (NR2), required
an aortic valve-in-valve implantation for bioprosthetic
valve failure (NR3), or required transfemoral or trans-
apical TAVR with a 29-mm prosthesis (NR5 and NR6,
respectively). Here we report the results for the inop-
erable, randomized cohort B patients.
STUDY DEVICE AND PROCEDURE. The SAPIEN
transcatheter heart valve and the SAPIEN XT have
been described previously (16). Brieﬂy, the SAPIEN
XT consists of bovine pericardium (in a partially
closed resting geometry) sewn to a balloon-
expandable thinner strut cobalt-chromium alloy
tubular frame. Both valves were available in 23- and
26-mm sizes and were implanted with the use of
dedicated transfemoral delivery systems. The SAPIEN
transcatheter valve was delivered with the RetroFlex
3 catheter, which required the use of 22- or 24-F
introducer sheaths. The SAPIEN XT was delivered
with the lower-proﬁle NovaFlex catheter, which
employed smaller 18- or 19-F introducer sheaths.
Patients were selected on the basis of having satis-
factory transarterial access for the larger 22- and 24-F
delivery systems. Balloon inﬂation was utilized to
expand the frame and secure it to the underlying
aortic valve annulus and leaﬂets.
All patients received aspirin (81 mg) and clopi-
dogrel ($300 mg) prior to the procedure, received
heparin during the procedure, and were maintained
on aspirin 81 mg indeﬁnitely. Clopidogrel was
continued for a minimum of 1 month. Patients with
atrial ﬁbrillation were placed on warfarin within 24 h
of the procedure.
STUDY DESIGN AND OVERSIGHT. The PARTNER II
study incorporated 2 parallel prospective,multicenter,
randomized, active-treatment–controlled clinical tri-
als. The study was designed jointly by the sponsor,
Edwards Lifesciences, and the PARTNER executive
committee. Patients were randomly assigned with the
use of a computer-generated scheme, blocked sepa-
rately at each participating site and for each ofthe trial cohorts. An independent clinical events
committee adjudicated all serious outcomes utilizing
the Valve Academic Research Consortium (VARC)
criteria (17). An independent data and safety moni-
toring board met frequently, had access to all study
data and treatment assignments, and recommended
after each meeting that the study be continued
without modiﬁcation. The executive committee met
in person every 8 to 12 weeks to monitor all other
aspects of the conduct of the trial. All data were
sent for analysis to independent consulting bio-
statisticians. Independent core laboratories analyzed
all electrocardiograms and echocardiograms. Authors
had unrestricted access to all study data after the
database was locked, made the decision to submit the
manuscript for publication, prepared all drafts of the
manuscript, and take responsibility for the integrity of
the data and the accuracy of the data analysis.
STUDY ENDPOINTS. The primary safety and effec-
tiveness endpoint was a nonhierarchical composite
of all-cause mortality, major stroke, or rehospitaliza-
tion at 1 year in the intention-to-treat population.
Pre-speciﬁed secondary endpoints included death
from cardiovascular causes, NYHA functional class,
myocardial infarction, stroke, acute kidney injury,
vascular complications, bleeding, 6-min walk dis-
tance, and echocardiography-assessed valve perfor-
mance. In this report, all patients were followed for
at least 2 years with annual clinical visits and echo-
cardiographic evaluations.
STATISTICAL ANALYSIS. We estimated that a sample
size of 458 patients would yield at least 80% power to
demonstrate noninferiority of SAPIEN XT to SAPIEN
with regard to the primary endpoint, assuming 1-year
composite event rates of 43.6% in both trial arms and
a noninferiority ratio of 1.35 at a 1-sided alpha of
0.025. The randomized sample size was set to 500
patients to allow for possible loss to follow-up and
other trial contingencies.
Statistical comparisons of the primary and other
endpoints between the SAPIEN and SAPIEN XT
groups were performed using Mann-Whitney U tests
for continuous variables and chi-square or Fisher
exact tests for categorical variables. Primary data
analysis was performed in the intention-to-treat
population, regardless of the treatment that was
actually received. Time-to-event analyses were per-
formed with the use of Kaplan-Meier estimates and
were compared between groups with the use of the
log-rank test. All statistical analyses were performed
with the use of SAS software version 9.2 (SAS Insti-
tute, Cary, North Carolina).
Webb et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 4 , 2 0 1 5
SAPIEN XT Compared to SAPIEN in Inoperable Patients With Severe Aortic Stenosis D E C E M B E R 2 1 , 2 0 1 5 : 1 7 9 7 – 8 0 6
1800RESULTS
PATIENTS AND ENROLLMENT. Between March 2011
and February 2012, 560 patients were enrolled at
28 sites in the United States and were randomly
assigned to TAVR with SAPIEN (n ¼ 276) or SAPIEN XT
(n ¼ 284). All patients were followed for least 2 years
(median follow-up 722.5 days; maximum 1,198 days).
The number of patients who underwent randomiza-
tion and follow-up is shown in Figure 1.
Baseline characteristics of the 2 groups were
similar (Table 1). The overall mean STS score (10.6%)
demonstrated high operative risk status. However,
there were also many patients with low STS scores
but with coexisting conditions that contributed
to the determination that the patient was not suit-
able for surgery, including frailty (59.6%), oxygen-
dependent respiratory difﬁculties (14.5%), porcelain
aorta (5.4%), chest wall radiation (3.9%), and chest
wall deformities (3.6%).
PROCEDURAL OUTCOMES. Among the 560 patients,
6 patients (2.2%) in the SAPIEN group and 2 patientsFIGURE 1 Study Flow Diagram(0.7%) in the SAPIEN XT group did not receive a
transcatheter valve. The reasons were death prior to
the index procedure or withdrawal from the study.
During the TAVR procedure or in the ﬁrst 24 h after
the procedure, 7 patients died (4 with SAPIEN and 3
with SAPIEN XT), 7 patients had major strokes (3 with
SAPIEN and 4 with SAPIEN XT), and 3 patients
had valve embolizations (1 with SAPIEN and 2 with
SAPIEN XT).
Several key intraprocedural differences were
observed between the 2 groups. The anesthesia
time was greater in SAPIEN patients compared with
SAPIEN XT (212.0  75.7 min vs. 197.6  60.8 min;
p ¼ 0.02). There was also a trend toward longer overall
procedure times with SAPIEN (109.3  57.3 min vs.
101.0  43.2 min; p ¼ 0.06), as well as more aborted
procedures (3.0% vs. 0.7%; p ¼ 0.06) and more
frequent intra-aortic balloon pump use (p ¼ 0.06).
DEATH, MAJOR STROKE, AND REPEAT HOSPITALI-
ZATION. At 30 days after randomization, all-cause
mortality was similar (5.1% with SAPIEN and 3.5%
with SAPIEN XT; p ¼ 0.36), as were rates of major
TABLE 1 Baseline Characteristics of Patients and Echocardiographic Findings
SAPIEN
(n ¼ 276)
SAPIEN XT
(n ¼ 284) p Value
Age, yrs 84.6  8.6 84.1  8.7 0.46
Male 142 (51.4) 141 (49.6) 0.67
STS score 11.0  5.71 10.29  5.38 0.15
Logistic EuroSCORE 21.0  17.0 18.8  14.6 0.10
NYHA functional class
II 11 (4) 9 (3.2) 0.60
III or IV 265 (96.0) 275 (96.8) 0.60
Coronary artery disease 186 (67.4) 186 (65.5) 0.63
Previous myocardial infarction 58 (21.0) 55 (19.4) 0.63
Previous intervention
CABG 72 (26.1) 76 (26.8) 0.86
PCI 100 (36.2) 90 (31.7) 0.26
Balloon aortic valvuloplasty 55 (19.9) 51 (18.0) 0.59
Carotid disease 44 (15.9) 49 (17.3) 0.68
Peripheral vascular disease 75 (27.2) 88 (31.0) 0.32
COPD
Any 72 (26.1) 84 (29.6) 0.36
Oxygen-dependent 43 (15.6) 38 (13.4) 0.46
Creatinine >2 mg/dl (177 mmol/l) 33 (12.0) 31 (10.9) 0.70
Atrial ﬁbrillation 112 (40.6) 104 (36.6) 0.34
Permanent pacemaker 47 (17.0) 59 (20.8) 0.26
Pulmonary hypertension 57 (20.7) 72 (25.4) 0.19
Frailty* 166 (60.1) 168 (59.2) 0.81
Extensively calciﬁed aorta 11 (4.0) 19 (6.7) 0.16
Deleterious effects of chest-wall irradiation 9 (3.3) 13 (4.6) 0.42
Chest-wall deformity 10 (3.6) 10 (3.5) 0.95
Liver disease 13 (4.7) 12 (4.2) 0.78
Echocardiographic ﬁndings
Effective aortic valve area, cm2 0.6  0.2 0.6  0.2 0.65
Mean aortic-valve gradient, mm Hg 45.1  14.3 45.1  13.6 0.99
Mean LVEF, % 52.9  13.8 52.4  13.5 0.71
Values are mean  SD or n (%). *Frailty was determined by the surgeons according to
pre-speciﬁed criteria.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease;
LVEF¼ left ventricular ejection fraction; NYHA¼ New York Heart Association; PCI¼ percutaneous
coronary intervention; STS ¼ Society of Thoracic Surgeons.
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1801stroke (3.0% vs. 3.2; p ¼ 0.85) and re-hospitalization
(10.6% vs. 11.6%; p ¼ 0.70) (Figure 2). The nonhier-
archical composite of all-cause mortality, major
stroke, and rehospitalization at 30 days was also
similar for SAPIEN and SAPIEN XT patients (15.7% vs.
17.0%; p ¼ 0.68).
At 1-year follow-up, the nonhierarchical com-
posite of all-cause mortality, major stroke, or
re-hospitalization (the primary endpoint) was 37.7%
in the SAPIEN group compared with 37.2% in the
SAPIEN XT group (p ¼ 0.90) (Table 2). The risk ratio of
the composite primary endpoint between the SAPIEN
XT group and the SAPIEN group was 0.99. On the
basis of a pre-speciﬁed noninferiority margin of 1.35,
the trial’s risk ratio met the criteria for noninferiority
(p < 0.002) with a 1-sided alpha of 0.025. Similarly,
there were no differences between the SAPIEN and
SAPIEN XT groups at 1-year follow-up for all-cause
mortality (23.3% vs. 22.3%; p ¼ 0.75), major stroke
(5.5% vs. 4.8%; p ¼ 0.76), or rehospitalization (24.1%
vs. 23.1%; p ¼ 0.79). At 2-year follow-up, there was
still no difference between the composite and indi-
vidual component endpoints.
OTHER CLINICAL OUTCOMES. At 30 days, vascular
complications were seen more frequently in patients
undergoing TAVR with the SAPIEN transcatheter
valve compared with SAPIEN XT (22.1% vs. 15.5%,
hazard ratio [HR]: 1.45; p ¼ 0.04) (Table 2). In
particular, the SAPIEN group experienced substan-
tially more major vascular complications than SAPIEN
XT (15.2% vs. 9.5%, HR: 1.61; p ¼ 0.04). Within the
subgroup of vascular complications, SAPIEN patients
had more frequent perforations than SAPIEN XT
patients (4.7% vs. 0.7%, HR: 6.71; p ¼ 0.003). Other
vascular complications, such as dissections and he-
matomas, were also numerically greater in the
SAPIEN group compared with SAPIEN XT but failed to
meet statistical signiﬁcance. Periprocedural bleeding
requiring blood transfusions was statistically more
frequent in the SAPIEN group compared with SAPIEN
XT (10.6% vs. 5.3%, HR: 2.02, 95% conﬁdence inter-
val: 1.08 to 3.76; p ¼ 0.02).
At 30 days and 1 year, there was signiﬁcant
improvement in NYHA symptoms compared with
baseline, with no differences between the 2 groups.
Nearly 85% of all patients had an improvement of at
least 1 NYHA functional class at 30 days, and 91%
had this improvement by 1 year. At 1 year, patients
in both groups experienced improved 6-min walk
distance; no signiﬁcant between-group differences
were observed.
ECHOCARDIOGRAPHIC FINDINGS. Effective aortic
valve area and gradients improved substantially withboth SAPIEN and SAPIEN XT from baseline to 30 days
(Table 3). In the SAPIEN cohort, the mean aortic valve
area increased from 0.62  0.17 cm2 at baseline to
1.530.40 cm2 post-procedure, and themean gradient
fell from 45.11  14.21 mmHg to 10.83 5.37 mmHg. In
the SAPIEN XT cohort, the mean aortic valve area
increased from 0.63  0.18 cm2 to 1.58  0.43 cm2, and
the mean gradient fell from 45.09  13.63 mm Hg to
10.03  3.85 mm Hg. Paravalvular regurgitation was
similar both devices at the time of discharge, at
30 days, and at 1-year follow-up. Although the ma-
jority of patients were found to have no or mild
paravalvular regurgitation, for both groups, approxi-
mately 20% of the patients had moderate or severe
paravalvular regurgitation at the time of discharge,
without important changes at 30-day and 1-year
follow-up.
FIGURE 2 Time-to-Event Curves for the Primary Composite Endpoint and Other Selected Endpoints at 1 and 2 Years
Time-to-event curves for the primary composite endpoint (A), all-cause mortality (B), major stroke (C), and rehospitalization (D). CI ¼ conﬁdence interval;
HR ¼ hazard ratio.
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1802DISCUSSION
In this randomized, multicenter study of the lower-
proﬁle SAPIEN XT valve compared with the original
SAPIEN valve in inoperable patients with severe,
symptomatic AS, there was no difference at 1 or
2 years in the nonhierarchical composite endpoint of
all-cause mortality, major stroke, or rehospitalization,
nor with any of the individual endpoints. However,
major vascular complications and bleeding requiring
transfusions were reduced with SAPIEN XT. Patients
undergoing TAVR with SAPIEN XT also required
shorter anesthesia time, with trends toward reduced
overall procedure time, fewer aborted procedures,
and a less frequent need for a second transcatheter
heart valve or intra-aortic balloon pump support.A distinguishing feature of the SAPIEN XT system
is its lower proﬁle, and as the present study demon-
strates, the reduced size of entry catheters and
sheaths resulted in meaningful reductions in both
vascular complications. The use of larger-proﬁle
devices (>20-F) coupled with a challenging an-
atomic substrate (older patients with frequent
peripheral vascular disease) resulted in 10% to 15%
major vascular complications in prior TAVR studies
(1,18,19). One of the strongest predictors of major
vascular complications after TAVR is a larger sheath-
to-femoral artery ratio (20,21), and thus, it was ex-
pected that a lower-proﬁle device would result in
fewer vascular complications. In the present trial, the
lower-proﬁle SAPIEN XT system led to a 6.5% abso-
lute reduction in all forms of vascular complications,
TABLE 2 Clinical Outcomes at 30 Days and 1 Year
30 Days
p Value*
1 Year
p Value*
SAPIEN
(n ¼ 276)
SAPIEN XT
(n ¼ 284)
SAPIEN
(n ¼ 276)
SAPIEN XT
(n ¼ 284)
Death, disabling stroke, or rehospitalization 43 (15.7) 48 (17.0) 0.68 102 (37.7) 105 (37.2) 0.90
Death 14 (5.1) 10 (3.5) 0.36 63 (23.3) 63 (22.3) 0.75
From cardiovascular cause 12 (4.4) 9 (3.2) 0.46 48 (18.2) 46 (16.6) 0.64
From noncardiovascular cause 2 (0.8) 1 (0.4) 0.54 15 (6.3) 17 (6.9) 0.66
Stroke or TIA 13 (4.8) 12 (4.3) 0.79 20 (7.8) 19 (7.1) 0.77
Major stroke 8 (3.0) 9 (3.2) 0.85 14 (5.5) 13 (4.8) 0.76
Minor stroke 3 (1.1) 3 (1.1) 0.97 3 (1.1) 5 (1.9) 0.51
Rehospitalization† 28 (10.6) 32 (11.6) 0.70 61 (24.1) 61 (23.1) 0.79
Myocardial infarction 1 (0.4) 5 (1.8) 0.22 6 (2.2) 11 (3.9) 0.33
Vascular complications 61 (22.1) 44 (15.6) 0.04 65 (23.7) 47 (16.7) 0.04
Major 42 (15.2) 27 (9.5) 0.04 44 (16.1) 29 (10.3) 0.04
Minor 20 (7.3) 15 (5.3) 0.33 20 (7.3) 15 (5.3) 0.33
Perforation 13 (4.7) 2 (0.7) 0.003 13 (4.7) 2 (0.7) 0.003
Dissection 23 (8.3) 14 (4.9) 0.11 23 (8.3) 15 (5.4) 0.15
Hematoma 13 (4.7) 5 (1.8) 0.05 13 (4.7) 5 (1.8) 0.05
Bleeding 101 (36.7) 94 (33.3) 0.40 124 (46.2) 122 (44.1) 0.58
Minor 22 (8.1) 26 (9.3) 0.73 35 (13.6) 38 (14.1) 0.80
Major 50 (18.3) 49 (17.5) 0.80 61 (23.2) 61 (22.2) 0.82
Disabling 34 (12.4) 22 (7.8) 0.77 52 (19.9) 38 (14.1) 0.07
Transfusion 29 (10.6) 15 (5.3) 0.02 39 (14.9) 28 (10.5) 0.10
Acute kidney injury 45 (16.8) 43 (15.4) 0.69 80 (31.3) 84 (31.0) 0.93
Aortic valve reintervention 11 (4.0) 8 (2.8) 0.44 12 (4.4) 11 (4.1) 0.75
Valve-in-valve 10 (3.6) 4 (1.4) 0.09 10 (3.6) 4 (1.4) 0.09
Aortic balloon valvuloplasty 1 (0.4) 1 (0.4) 0.99 1 (0.4) 1 (0.4) 0.99
Surgical aortic valve replacement 0 (0.0) 2 (0.7) 0.16 0 (0.0) 2 (0.7) 0.16
Other 0 (0.0) 1 (0.4) 0.33 1 (0.4) 3 (1.2) 0.35
Pacemaker 16 (5.9) 19 (6.8) 0.66 21 (8.0) 22 (8.1) 0.96
Coronary obstruction 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA
New York Heart Association functional class
I 90 (36.1) 97 (36.1) 0.86 80 (41.7) 99 (48.5) 0.17
II 99 (39.8) 107 (40.7) 0.83 82 (42.7) 81 (39.7) 0.54
III and V 60 (24.1) 59 (22.4) 0.66 30 (15.6) 24 (11.8) 0.26
6-min walk time, min 128.55  120.86 133.88  117.24 0.62 132.30  136.34 158.99  138.51 0.08
Change in 6-min walk time, min 40.57  102.81 35.99  103.39 0.63 41.38  113.19 52.74  111.53 0.37
Values are n (%) or mean  SD. *The p values are for between-group comparisons of the frequency of the event at each time point. †Repeat hospitalizations were included if
they were due to aortic stenosis or complications of the valve procedure (e.g., transcatheter aortic valve replacement). NA ¼ not available.
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1803a 5.7% absolute reduction in major vascular compli-
cations, and a 4% reduction in perforations at 30
days. This reduction in vascular complications has
important clinical implications because it has previ-
ously been shown that major vascular complications
are associated with increased major bleeding, renal
failure requiring dialysis, and mortality at both 30
days and 1 year (14).
Several prior studies have established the harmful
effects of blood transfusions after a cardiovascular
procedure, including an increase in the risk of infec-
tion, ischemic events, length of stay, and hospital
costs (22–24). In particular, bleeding requiring trans-
fusion after TAVR has been associated with higher30-day and 1-year mortality and increased risk of
major stroke and acute kidney injury (24–26). The use
of SAPIEN XT in this trial resulted in a 2-fold reduc-
tion in bleeding requiring transfusion at 30 days,
which has important implications in improving
overall clinical outcomes.
The primary ﬁndings of this randomized trial
are in direct accordance with previously reported
SAPIEN XT registries (27–31). However, the rate of
moderate or severe paravalvular regurgitation in
the present trial is nearly double the rate reported
in other trials or registries of balloon-expandable
transcatheter valves. In the PARTNER IB trial,
the SAPIEN valve was associated with rates of
TABLE 3 Echocardiographic Outcomes at 30 Days and 1 Year
Outcome
30 Days
p Value
1 Year
p Value
SAPIEN
(n ¼ 276)
SAPIEN XT
(n ¼ 284)
SAPIEN
(n ¼ 276)
SAPIEN XT
(n ¼ 284)
AV area, cm2 1.53  0.40 1.58  0.43 0.20 1.50  0.40 1.48  0.43 0.64
AV area indexed, cm2/kg 0.85  0.24 0.87  0.24 0.37 0.83  0.24 0.81  0.24 0.49
AV mean gradient, mm Hg 10.83  5.37 10.03  3.85 0.06 11.35  6.42 11.33  4.59 0.98
AV peak gradient, mm Hg 21.42  9.85 19.95  7.74 0.07 22.29  11.61 22.67  9.04 0.73
Left ventricular ejection fraction, % 54.86  11.93 53.80  11.79 0.41 55.12  10.82 56.35  11.02 0.40
Transvalvular aortic regurgitation
None 123 (53) 178 (73.9) <0.0001 90 (56.6) 122 (70.1) 0.01
Trace 67 (28.9) 52 (21.6) 0.07 40 (25.2) 41 (23.6) 0.73
Mild 38 (16.4) 11 (4.6) <0.0001 22 (13.8) 9 (5.2) 0.007
Moderate 4 (1.7) 0 (0) 0.057 7 (4.4) 1 (0.6) 0.03
Severe 0 (0) 0 (0) NA 0 (0) 1 (0.6) 1.00
Paravalvular aortic regurgitation
None 35 (14.9) 23 (9.5) 0.07 29 (18.0) 24 (13.5) 0.25
Trace 59 (25.1) 69 (28.4) 0.42 38 (23.6) 50 (28.1) 0.35
Mild 101 (43) 92 (37.9) 0.25 60 (37.3) 55 (30.9) 0.22
Moderate 34 (14.5) 55 (22.6) 0.02 33 (20.5) 45 (25.3) 0.30
Severe 6 (2.6) 4 (1.6) 0.54 1 (0.6) 4 (2.2) 0.37
Total aortic regurgitation
None 16 (6.8) 16 (6.5) 0.90 20 (12.3) 20 (11.2) 0.75
Trace 64 (27.2) 72 (29.4) 0.60 39 (23.9) 48 (26.8) 0.54
Mild 104 (44.3) 96 (39.2) 0.26 66 (40.5) 60 (33.5) 0.18
Moderate 44 (18.7) 57 (23.3) 0.22 32 (19.6) 45 (25.1) 0.22
Severe 7 (3.0) 4 (1.6) 0.32 6 (3.7) 6 (3.4) 0.87
Values are mean  SD or n (%).
AV ¼ aortic valve; NA ¼ not available.
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1804moderate or severe paravalvular regurgitation of
11.8% at 30 days and 10.5% at 1 year. In contrast,
the current study reports higher rates with the
same valve of 17.1% at 30 days and 21.1% at 1 year
(1). We believe that this difference in the inci-
dence of paravalvular regurgitation using the same
model of transcatheter valve and targeting similar
patient populations is likely due to differences in the
methods used by the echocardiography core labora-
tories to grade paravalvular regurgitation. The 2
trials utilized different echocardiographic core labo-
ratories with differing methodologies. Unlike the
methods used by the PARTNER 1 core laboratory for
paravalvular regurgitation assessment, the core lab-
oratory for this trial used the American Society
of Echocardiography guidelines with the lower
circumferential extent criteria; speciﬁcally, para-
valvular regurgitation was considered severe when
the regurgitant jet was >20% of the short axis
annular circumference. Moreover, circumferential
extent was weighted more heavily than other pa-
rameters by the echocardiographic core laboratory
of this trial.A recent PARTNER IIB analysis demonstrated that
when a consortium of echocardiography core labora-
tory directors re-reviewed 100 randomly chosen
echocardiograms from this trial, there was a systemic
overestimation of greater than mild paravalvular
regurgitation by the PARTNER IIB core laboratory;
15.9% of patients graded by the core laboratory as
having moderate paravalvular regurgitation would
have been graded as having mild paravalvular
regurgitation by the consortium of laboratory di-
rectors (32). This ﬁnding underscores the difﬁculty
with accurate and consistent assessment of post-
TAVR paravalvular regurgitation severity due to
the fact that paravalvular regurgitation jets are
frequently multiple in number, irregular in shape,
and eccentric in direction. Moreover, echocardio-
graphic guidelines, which have been developed for
assessing the severity of paravalvular regurgitation
for surgical prostheses, have not been well validated
for transcatheter valves. These pitfalls could have
led to difﬁculty achieving consistent paravalvular
regurgitation assessments between echocardiography
core laboratories.
PERSPECTIVES
WHAT IS KNOWN? TAVR with the SAPIEN transcatheter heart
valve in inoperable patients with severe AS has been shown to
be superior to standard therapy. However, whether the lower-
proﬁle SAPIEN XT transcatheter heart valve compares favorably
to the original SAPIEN transcatheter valve remains unknown.
WHAT IS NEW? There was no difference in all-cause mortality,
major stroke, or rehospitalization between SAPIEN and
SAPIEN XT, but the SAPIEN XT was associated with less
vascular complications and bleeding requiring transfusion.
WHAT IS NEXT? Evaluation of the even newer SAPIEN 3
transcatheter heart valve compared with the SAPIEN and SAPIEN
XT transcatheter valves.
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1805Of note, although the construct of the present trial
is similar to the original PARTNER IB trial in many
ways, there are important methodological differ-
ences. PARTNER IIB applied more rigorous clinical
trial methodologies, including utilizing VARC criteria
for assessing outcomes to facilitate meaningful com-
parisons with other clinical trials (17). Moreover, un-
like the original PARTNER I trial, the present trial
required all enrolled patients to undergo strict
neurological assessments before TAVR and at regular,
pre-speciﬁed intervals afterward. Nevertheless,
despite the mandated neurological evaluations, the
stroke frequency was not higher, but rather was lower
than in PARTNER IB. Major strokes occurred in 5% at
30 days and 7.8% at 1 year in PARTNER IB, whereas
the combined major stroke rate for both the SAPIEN
and SAPIEN XT valves in the present trial was 3.1% at
30 days and 5.2% at 1 year. The lower stroke rate is
not unexpected, as several studies have indicated
that the stroke frequency after TAVR has been
declining in recent years due to improved case se-
lection, procedural technique reﬁnements, increased
operator experience, and new TAVR systems (33).
STUDY LIMITATIONS. First, shortly after adjudica-
tion of clinical events had begun with this trial, the
updated VARC-2 criteria were developed (34). Given
that the trial was designed and powered with the
original VARC criteria, the decision was made by the
executive committee and sponsor to continue adju-
dication utilizing the original VARC criteria. Second,
after enrollment of the PARTNER IIB trial was largely
complete, newer and even lower proﬁle 16- and 18-F
expandable sheaths (eSheath, Edwards Lifesciences)
were developed for the delivery of the SAPIEN XT
valves. It is possible that the use of these sheaths
in our trial may have resulted in further improve-
ments in vascular and bleeding complications,
although a recent study did not demonstrate such an
advantage (35). Third, the heart team’s determinationof inoperability may have changed compared with the
earlier PARTNER IB study due to increased clinical
experience with TAVR over time. Last, as previously
discussed, this trial employed a different echocardi-
ography core laboratory that, upon re-review, sys-
temically overestimated the severity of paravalvular
regurgitation.
CONCLUSIONS
The SAPIEN XT is an incremental improvement from
the prior generation of TAVR technology with a
reduced risk of vascular injury and bleeding events
requiring transfusion. The SAPIEN XT should be
regarded as the next standard of care for patients
undergoing balloon-expandable TAVR.
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